Kinnate Biopharma Past Earnings Performance
Past criteria checks 0/6
Kinnate Biopharma's earnings have been declining at an average annual rate of -40.2%, while the Biotechs industry saw earnings growing at 17.7% annually.
Key information
-40.2%
Earnings growth rate
7.6%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -73.7% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Kinnate Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -127 | 30 | 103 |
| 30 Jun 23 | 0 | -127 | 31 | 102 |
| 31 Mar 23 | 0 | -122 | 31 | 95 |
| 31 Dec 22 | 0 | -116 | 30 | 88 |
| 30 Sep 22 | 0 | -111 | 30 | 82 |
| 30 Jun 22 | 0 | -105 | 28 | 78 |
| 31 Mar 22 | 0 | -99 | 26 | 74 |
| 31 Dec 21 | 0 | -90 | 23 | 67 |
| 30 Sep 21 | 0 | -77 | 18 | 60 |
| 30 Jun 21 | 0 | -63 | 14 | 49 |
| 31 Mar 21 | 0 | -49 | 11 | 39 |
| 31 Dec 20 | 0 | -36 | 7 | 29 |
| 30 Sep 20 | 0 | -26 | 6 | 20 |
| 31 Dec 19 | 0 | -10 | 3 | 9 |
Quality Earnings: 6KB is currently unprofitable.
Growing Profit Margin: 6KB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6KB is unprofitable, and losses have increased over the past 5 years at a rate of 40.2% per year.
Accelerating Growth: Unable to compare 6KB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6KB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.2%).
Return on Equity
High ROE: 6KB has a negative Return on Equity (-73.75%), as it is currently unprofitable.